Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 257

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 257
---
 issued by us to the Selling Securityholder under the New Keystone Purchase Agreement. As used in this prospectus, the term “ Selling Securityholder” includes Keystone, and its permitted pledgees, donees, transferees, assignees, successors, designees, successors-in-interest and others who later come to hold any of Keystone’s interest in the shares of Common Stock in accordance with the terms of the applicable agreements governing their respective registration rights, other than through a public sale. This prospectus also covers any additional securities that may become issuable by reason of stock splits, stock dividends or other similar transactions. For additional information regarding the issuance of Common Stock covered by this prospectus, see the section entitled “ The Committed Equity Financing” above. We are registering shares of our Common Stock pursuant to the provisions of the Keystone Purchase Agreements and the Keystone Registration Rights Agreements in order to permit the Selling Securityholder to offer the shares for resale from time to time. Except for the transactions contemplated by the Keystone Purchase Agreements and the Keystone Registration Rights Agreements and the Securities Purchase Agreements, the Selling Securityholder have not had any material relationship with us within the past three years. The following table was prepared based on information provided to us by Keystone and provides, as of the date of this prospectus, information regarding the beneficial ownership of our Common Stock of Keystone, the number of securities that may be sold by Keystone under this prospectus, and the number of securities that Keystone will beneficially own assuming all securities that may be offered pursuant to this prospectus are sold, and without taking into account any limitations on conversion of the Preferred Shares or exercise of the PIPE Warrants. Because Keystone may dispose of all, none or some portion of their securities, no estimate can be given as to the number of securities that will be beneficially owned by Keystone upon termination of this offering. For purposes of the table below, however, we have assumed that after termination of this offering, none of the securities covered by this prospectus will be beneficially owned by Keystone and further assumed that Keystone will not acquire beneficial ownership of any additional securities during the offering. In addition, Keystone may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at any time and from time to time, our securities in transactions exempt from the registration requirements of the Securities Act after the date on which the information in the table is presented. Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the